Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

Mass General Brigham Ventures

Monashee Investment Management

Aisling Capital

Ridgeback Capital

Sectoral Asset Management

Northpond Ventures

OrbiMed

Resilience

Cormorant Asset Management

Alexandria Venture Investments

Garuda Therapeutics

March 1 is #EmployeeAppreciationDay! Made up of science-driven individuals with a passion for serving patients, the #GarudaTx team is making our mission to build the future of blood #stemcell therapies a reality. 
 
Today and every day, we are incredibly grateful for the Garuda team and their dedication to delivering transformative medicines to patients.

Garuda is proud to recognize February 29 as #RareDiseaseDay – a day dedicated to raising awareness and inspiring action for the 300 million people living with a #RareDisease worldwide. 
 
At Garuda, we’re developing off-the-shelf, durable blood stem cell therapies with the potential to provide curative treatment options to millions of patients with rare diseases. 
 
Learn more about our approach: bit.ly/3NrS9t0

What does 2024 hold for #biopharma?
 
Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah expects an increased appetite for off-the-shelf blood stem cell therapies due to their ability to bypass many challenges associated with current treatment options.
 
Check it out: bit.ly/49BZlfA

Congratulations to Rob Labriola, Executive Director of Regulatory Operations at Garuda, who has been selected to serve on the Drug Information Association (DIA) conference planning committee for DIA’s Regulatory Submissions, Information, and Document Management (RSIDM) Forum, taking place February 12-14, 2024 in North Bethesda, MD.
 
Rob will also lead the Forum track on Building and Sustaining Successful RSIDM Foundations. Register for this can’t miss event which will feature over 90 diverse speakers from regulatory, industry and academia: bit.ly/48PqknX

Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT.
 
We look forward to connecting in San Francisco.

Hemgenix is a biotech company specializing in gene therapies for rare diseases.

Hemgenix

Skysona is a biotech company known for its innovative gene therapy treatments for rare diseases.

Skysona

Zynteglo is a biotech company that has developed gene therapy treatments for rare diseases.

Zynteglo

Zolgensma is a biotech company specializing in gene therapies for rare diseases.

Zolgensma

Luxturna is a biotech company focused on developing gene therapy treatments for rare diseases.

Luxturna

Biogen is a large drugmaker involved in gene therapy for rare diseases.

Biogen

Johnson & Johnson is a pharmaceutical company with a focus on gene therapy for rare diseases.

Johnson & Johnson

Pfizer is a leading pharmaceutical company involved in gene therapy for rare diseases.

Pfizer

GarudaTx is a biotechnology company focused on developing innovative therapies for rare diseases. The company leverages its proprietary gene therapy platform to create treatments that address unmet medical needs.

GarudaTx

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 8:37 AM	6d4f283e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	f16bacbb
crunchbase profile	general
li profile	general	May 16, 2024 8:37 AM	05d86610
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GARUDATX

GarudaTx